6,500 Shares in Celcuity, Inc. $CELC Acquired by SBI Okasan Asset Management Co.Ltd.

SBI Okasan Asset Management Co.Ltd. bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC) during the 4th quarter, HoldingsChannel.com reports. The fund bought 6,500 shares of the company’s stock, valued at approximately $660,000.

Several other large investors have also recently added to or reduced their stakes in CELC. Creative Planning purchased a new stake in Celcuity during the 2nd quarter worth approximately $177,000. Rhumbline Advisers increased its stake in Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after buying an additional 503 shares during the period. XTX Topco Ltd purchased a new stake in Celcuity during the 2nd quarter worth approximately $169,000. Quantinno Capital Management LP increased its stake in Celcuity by 20.7% during the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock worth $3,245,000 after buying an additional 41,756 shares during the period. Finally, Paloma Partners Management Co increased its stake in Celcuity by 285.8% during the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock worth $1,097,000 after buying an additional 60,849 shares during the period. 63.33% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Celcuity

In other news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. The trade was a 27.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 37,000 shares of company stock valued at $5,111,950. Company insiders own 13.33% of the company’s stock.

Celcuity Trading Up 1.5%

Shares of Celcuity stock opened at $132.88 on Friday. The company has a fifty day simple moving average of $123.09 and a 200-day simple moving average of $110.94. Celcuity, Inc. has a 12-month low of $10.50 and a 12-month high of $151.02. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The stock has a market cap of $6.48 billion, a price-to-earnings ratio of -34.07 and a beta of 0.09.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10. On average, equities analysts forecast that Celcuity, Inc. will post -3.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on CELC. Weiss Ratings downgraded shares of Celcuity from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. Needham & Company LLC reissued a “buy” rating and issued a $157.00 price objective on shares of Celcuity in a research report on Friday, May 15th. Stifel Nicolaus set a $150.00 price objective on shares of Celcuity in a research report on Monday, May 4th. Macquarie Infrastructure set a $160.00 price objective on shares of Celcuity in a research report on Thursday. Finally, Wolfe Research reissued an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $150.27.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.